High materiality7/10
Guggenheim Raises Rapport Therapeutics Price Target to $70
Why it may matterVerify against the original reporting
Bullish, though the unusually large target gap warrants caution.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Guggenheim raised its RAPP price target; the stated $70 target is about 138% above the posted price of $29.37.
- The target implies unusually large upside; this remains a single analyst forecast.
Key facts
- 01
Target: $70
- 02
Posted price: $29.37
- 03
Analyst firm: Guggenheim
- 04
Analyst: Delma Caiati
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.